{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:16:53Z","timestamp":1788405413852,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk\u2013benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes.<\/jats:p>","DOI":"10.1007\/s40520-022-02272-z","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T07:03:27Z","timestamp":1667545407000},"page":"2625-2634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Novel formulations of oral bisphosphonates in the treatment of osteoporosis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-2255","authenticated-orcid":false,"given":"Nicholas","family":"Fuggle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radmila","family":"Matijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis Pierre","family":"Radermecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Thomasius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sansin","family":"Tuzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"2272_CR1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40520-021-01845-8","volume":"33","author":"JM Kaufman","year":"2021","unstructured":"Kaufman JM (2021) Management of osteoporosis in older men. Aging Clin Exp Res 33:1439\u20131452. https:\/\/doi.org\/10.1007\/s40520-021-01845-8","journal-title":"Aging Clin Exp Res"},{"key":"2272_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40520-021-01817-y","volume":"33","author":"J Barnsley","year":"2021","unstructured":"Barnsley J, Buckland G, Chan PE et al (2021) Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res 33:759\u2013773. https:\/\/doi.org\/10.1007\/s40520-021-01817-y","journal-title":"Aging Clin Exp Res"},{"key":"2272_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4321\/S1889-836X2016000100003","volume":"8","author":"J Blanch","year":"2016","unstructured":"Blanch J, Gonz\u00e1lez E, Vald\u00e9s C et al (2016) Medical professionals\u2019 perceptions regarding therapeutic adherence in patients with osteoporosis. Rev Osteoporos Metab Miner 8:15\u201323. https:\/\/doi.org\/10.4321\/S1889-836X2016000100003","journal-title":"Rev Osteoporos Metab Miner"},{"key":"2272_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/qjmed\/hcq259","volume":"104","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281\u2013300. https:\/\/doi.org\/10.1093\/qjmed\/hcq259","journal-title":"QJM"},{"key":"2272_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"2272_CR6","unstructured":"Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice G (1990) In: Field MJ and Lohr KN (eds) Clinical Practice Guidelines: Directions for a New Program. Washington (DC): National Academies Press (US) Copyright \u00a9 National Academy of Sciences"},{"key":"2272_CR7","unstructured":"Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G (2011) In: Graham R, Mancher M, Miller Wolman D, et al. (eds) Clinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US) Copyright 2011 by the National Academy of Sciences. All rights reserved"},{"key":"2272_CR8","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s40520-021-01898-9","volume":"33","author":"A De Vincentis","year":"2021","unstructured":"De Vincentis A, Behr AU, Bellelli G et al (2021) Orthogeriatric co-management for the care of older subjects with hip fracture: recommendations from an Italian intersociety consensus. Aging Clin Exp Res 33:2405\u20132443. https:\/\/doi.org\/10.1007\/s40520-021-01898-9","journal-title":"Aging Clin Exp Res"},{"key":"2272_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/gl-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract 26:564\u2013570. https:\/\/doi.org\/10.4158\/gl-2020-0524","journal-title":"Endocr Pract"},{"key":"2272_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporos Int"},{"key":"2272_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40520-022-02100-4","volume":"34","author":"EM Curtis","year":"2022","unstructured":"Curtis EM, Reginster JY, Al-Daghri N et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34:695\u2013714. https:\/\/doi.org\/10.1007\/s40520-022-02100-4","journal-title":"Aging Clin Exp Res"},{"key":"2272_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"2272_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","volume":"38","author":"H Kondo","year":"2020","unstructured":"Kondo H, Okimoto N, Yoshioka T et al (2020) Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. J Bone Miner Metab 38:894\u2013902. https:\/\/doi.org\/10.1007\/s00774-020-01126-w","journal-title":"J Bone Miner Metab"},{"key":"2272_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/nejm199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T et al (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265\u20131271. https:\/\/doi.org\/10.1056\/nejm199005033221803","journal-title":"N Engl J Med"},{"key":"2272_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/nejm199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts NB, Harris ST, Genant HK et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73\u201379. https:\/\/doi.org\/10.1056\/nejm199007123230201","journal-title":"N Engl J Med"},{"key":"2272_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"key":"2272_CR17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082. https:\/\/doi.org\/10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"key":"2272_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352. https:\/\/doi.org\/10.1001\/jama.282.14.1344","journal-title":"JAMA"},{"key":"2272_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391. https:\/\/doi.org\/10.1007\/s001980050010","journal-title":"Osteoporos Int"},{"key":"2272_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/nejm200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340. https:\/\/doi.org\/10.1056\/nejm200102013440503","journal-title":"N Engl J Med"},{"key":"2272_CR21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","volume":"107","author":"AD Anastasilakis","year":"2022","unstructured":"Anastasilakis AD, Pepe J, Napoli N et al (2022) Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab 107:1441\u20131460. https:\/\/doi.org\/10.1210\/clinem\/dgab888","journal-title":"J Clin Endocrinol Metab"},{"key":"2272_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Miner Res 31:16\u201335. https:\/\/doi.org\/10.1002\/jbmr.2708","journal-title":"J Bone Miner Res"},{"key":"2272_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","volume":"27","author":"A Khan","year":"2016","unstructured":"Khan A, Morrison A, Cheung A et al (2016) Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int 27:853\u2013859. https:\/\/doi.org\/10.1007\/s00198-015-3335-3","journal-title":"Osteoporos Int"},{"key":"2272_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","volume":"22","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R, Akesson K, Bouxsein M et al (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report. Osteoporos Int 22:373\u2013390. https:\/\/doi.org\/10.1007\/s00198-010-1453-5","journal-title":"Osteoporos Int"},{"key":"2272_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323. https:\/\/doi.org\/10.1002\/jbmr.1998","journal-title":"J Bone Miner Res"},{"key":"2272_CR26","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbmr.1719","volume":"27","author":"RM Dell","year":"2012","unstructured":"Dell RM, Adams AL, Greene DF et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544\u20132550. https:\/\/doi.org\/10.1002\/jbmr.1719","journal-title":"J Bone Miner Res"},{"key":"2272_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/ENDO:23:1:01","volume":"23","author":"SI McFarlane","year":"2004","unstructured":"McFarlane SI, Muniyappa R, Shin JJ et al (2004) Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 23:1\u201310. https:\/\/doi.org\/10.1385\/ENDO:23:1:01","journal-title":"Endocrine"},{"key":"2272_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1191\/0961203305lu2219oa","volume":"14","author":"M Bevilacqua","year":"2005","unstructured":"Bevilacqua M, Dominguez LJ, Rosini S et al (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:773\u2013779. https:\/\/doi.org\/10.1191\/0961203305lu2219oa","journal-title":"Lupus"},{"key":"2272_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0021-9150(77)90161-7","volume":"27","author":"WD Wagner","year":"1977","unstructured":"Wagner WD, Clarkson TB, Foster J (1977) Contrasting effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the regression of two types of dietary-induced atherosclerosis. Atherosclerosis 27:419\u2013435. https:\/\/doi.org\/10.1016\/0021-9150(77)90161-7","journal-title":"Atherosclerosis"},{"key":"2272_CR30","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1126\/science.6792706","volume":"213","author":"DM Kramsch","year":"1981","unstructured":"Kramsch DM, Aspen AJ, Rozler LJ (1981) Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science (New York, NY) 213:1511\u20131512. https:\/\/doi.org\/10.1126\/science.6792706","journal-title":"Science (New York, NY)"},{"key":"2272_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1006\/rtph.2002.1550","volume":"35","author":"M Steinbuch","year":"2002","unstructured":"Steinbuch M, D\u2019Agostino RB, Mandel JS et al (2002) Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 35:320\u2013326. https:\/\/doi.org\/10.1006\/rtph.2002.1550","journal-title":"Regul Toxicol Pharmacol"},{"key":"2272_CR32","doi-asserted-by":"publisher","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","volume":"10","author":"DH Kim","year":"2015","unstructured":"Kim DH, Rogers JR, Fulchino LA et al (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS ONE 10:e0122646. https:\/\/doi.org\/10.1371\/journal.pone.0122646","journal-title":"PLoS ONE"},{"key":"2272_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","volume":"103","author":"TJ Bunch","year":"2009","unstructured":"Bunch TJ, Anderson JL, May HT et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824\u2013828. https:\/\/doi.org\/10.1016\/j.amjcard.2008.11.037","journal-title":"Am J Cardiol"},{"key":"2272_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/m18-0543","volume":"169","author":"S De Geest","year":"2018","unstructured":"De Geest S, Zullig LL, Dunbar-Jacob J et al (2018) ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med 169:30\u201335. https:\/\/doi.org\/10.7326\/m18-0543","journal-title":"Ann Intern Med"},{"key":"2272_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691\u2013705. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04167.x","journal-title":"Br J Clin Pharmacol"},{"key":"2272_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00198-021-06108-w","volume":"33","author":"F Thomasius","year":"2022","unstructured":"Thomasius F, Palacios S, Alam A et al (2022) Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Osteoporos Int 33:217\u2013228. https:\/\/doi.org\/10.1007\/s00198-021-06108-w","journal-title":"Osteoporos Int"},{"key":"2272_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","volume":"25","author":"MA Fischer","year":"2010","unstructured":"Fischer MA, Stedman MR, Lii J et al (2010) Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 25:284\u2013290. https:\/\/doi.org\/10.1007\/s11606-010-1253-9","journal-title":"J Gen Intern Med"},{"key":"2272_CR38","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ et al (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507\u20131529. https:\/\/doi.org\/10.1007\/s00198-016-3894-y","journal-title":"Osteoporos Int"},{"key":"2272_CR39","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.2106\/jbjs.G.00864","volume":"90","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Vanoverloop J, Fabri V et al (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Jt Surg Am 90:2142\u20132148. https:\/\/doi.org\/10.2106\/jbjs.G.00864","journal-title":"J Bone Jt Surg Am"},{"key":"2272_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385. https:\/\/doi.org\/10.1016\/8756-3282(95)00445-9","journal-title":"Bone"},{"key":"2272_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/tcrm.S52291","volume":"9","author":"M Pazianas","year":"2013","unstructured":"Pazianas M, Abrahamsen B, Ferrari S et al (2013) Eliminating the need for fasting with oral administration of bisphosphonates. Ther Clin Risk Manag 9:395\u2013402. https:\/\/doi.org\/10.2147\/tcrm.S52291","journal-title":"Ther Clin Risk Manag"},{"key":"2272_CR42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3109\/13697137.2014.995164","volume":"18","author":"M Vytrisalova","year":"2015","unstructured":"Vytrisalova M, Touskova T, Ladova K et al (2015) Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. Climacteric 18:608\u2013616. https:\/\/doi.org\/10.3109\/13697137.2014.995164","journal-title":"Climacteric"},{"key":"2272_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","volume":"52","author":"TF Blaschke","year":"2012","unstructured":"Blaschke TF, Osterberg L, Vrijens B et al (2012) Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 52:275\u2013301. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011711-113247","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2272_CR44","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T et al (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"2272_CR45","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","volume":"41","author":"P Fardellone","year":"2019","unstructured":"Fardellone P, Lello S, Cano A et al (2019) Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review. Clin Ther 41:1576\u20131588. https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.001","journal-title":"Clin Ther"},{"key":"2272_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194350","author":"H Lee","year":"2021","unstructured":"Lee H, Lee S, Kim D et al (2021) Effect of dosing interval on compliance of osteoporosis patients on bisphosphonate therapy: observational study using nationwide insurance claims data. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10194350","journal-title":"J Clin Med"},{"key":"2272_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-018-04821-7","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY (2019) Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporos Int 30:649\u2013658. https:\/\/doi.org\/10.1007\/s00198-018-04821-7","journal-title":"Osteoporos Int"},{"key":"2272_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2474-8-97","volume":"8","author":"J Adachi","year":"2007","unstructured":"Adachi J, Lynch N, Middelhoven H et al (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 8:97. https:\/\/doi.org\/10.1186\/1471-2474-8-97","journal-title":"BMC Musculoskelet Disord"},{"key":"2272_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.bonr.2015.10.006","volume":"4","author":"ES Siris","year":"2016","unstructured":"Siris ES, Fan CS, Yang X et al (2016) Association between gastrointestinal events and compliance with osteoporosis therapy. Bone Rep 4:5\u201310. https:\/\/doi.org\/10.1016\/j.bonr.2015.10.006","journal-title":"Bone Rep"},{"key":"2272_CR50","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bonr.2016.07.005","volume":"5","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Barron R et al (2016) Hospitalizations for osteoporosis-related fractures: Economic costs and clinical outcomes. Bone Rep 5:186\u2013191. https:\/\/doi.org\/10.1016\/j.bonr.2016.07.005","journal-title":"Bone Rep"},{"key":"2272_CR51","doi-asserted-by":"publisher","first-page":"e016982","DOI":"10.1136\/bmjopen-2017-016982","volume":"8","author":"RL Cutler","year":"2018","unstructured":"Cutler RL, Fernandez-Llimos F, Frommer M et al (2018) Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open 8:e016982. https:\/\/doi.org\/10.1136\/bmjopen-2017-016982","journal-title":"BMJ Open"},{"key":"2272_CR52","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","volume":"36","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M, Branco J, Brandi ML et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther 36:2811\u20132824. https:\/\/doi.org\/10.1007\/s12325-019-01063-9","journal-title":"Adv Ther"},{"key":"2272_CR53","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00198-019-05104-5","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30:2155\u20132165. https:\/\/doi.org\/10.1007\/s00198-019-05104-5","journal-title":"Osteoporos Int"},{"key":"2272_CR54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00198-019-05142-z","volume":"31","author":"CM Parsons","year":"2020","unstructured":"Parsons CM, Harvey N, Shepstone L et al (2020) Systematic screening using FRAX(\u00ae) leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int 31:67\u201375. https:\/\/doi.org\/10.1007\/s00198-019-05142-z","journal-title":"Osteoporos Int"},{"key":"2272_CR55","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D, de Kunder S, Si L et al (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31:1645\u20131669. https:\/\/doi.org\/10.1007\/s00198-020-05378-0","journal-title":"Osteoporos Int"},{"key":"2272_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40520-014-0256-5","volume":"27","author":"M Invernizzi","year":"2015","unstructured":"Invernizzi M, Cisari C, Carda S (2015) The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin Exp Res 27:107\u2013113. https:\/\/doi.org\/10.1007\/s40520-014-0256-5","journal-title":"Aging Clin Exp Res"},{"key":"2272_CR57","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1023\/a:1018894827961","volume":"43","author":"CP Peter","year":"1998","unstructured":"Peter CP, Handt LK, Smith SM (1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43:1998\u20132002. https:\/\/doi.org\/10.1023\/a:1018894827961","journal-title":"Dig Dis Sci"},{"key":"2272_CR58","unstructured":"EMC (2022) Binosto 70 mg effervescent tablets: patient information leaflet (PIL), https:\/\/www.medicines.org.uk\/emc\/product\/7113\/pil#gref. Accessed 31 July 2022"},{"key":"2272_CR59","doi-asserted-by":"publisher","first-page":"e10510","DOI":"10.1002\/jbm4.10510","volume":"5","author":"S Minisola","year":"2021","unstructured":"Minisola S, Vargas AP, Letizia Mauro G et al (2021) A prospective open-label observational study of a buffered soluble 70 mg alendronate effervescent tablet on upper gastrointestinal safety and medication errors: the GastroPASS study. JBMR Plus 5:e10510. https:\/\/doi.org\/10.1002\/jbm4.10510","journal-title":"JBMR Plus"},{"key":"2272_CR60","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archinte.160.4.517","volume":"160","author":"DC Bauer","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K et al (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517\u2013525. https:\/\/doi.org\/10.1001\/archinte.160.4.517","journal-title":"Arch Intern Med"},{"key":"2272_CR61","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/pl00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461\u2013468. https:\/\/doi.org\/10.1007\/pl00004171","journal-title":"Osteoporos Int"},{"key":"2272_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/jbmr.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u2013151. https:\/\/doi.org\/10.1359\/jbmr.040920","journal-title":"J Bone Miner Res"},{"key":"2272_CR63","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G et al (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1\u201312","journal-title":"Aging (Milano)"},{"key":"2272_CR64","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s40520-020-01777-9","volume":"33","author":"A Giusti","year":"2021","unstructured":"Giusti A, Bianchi G, Barone A et al (2021) A novel effervescent formulation of oral weekly alendronate (70\u00a0mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. Aging Clin Exp Res 33:2529\u20132537. https:\/\/doi.org\/10.1007\/s40520-020-01777-9","journal-title":"Aging Clin Exp Res"},{"key":"2272_CR65","doi-asserted-by":"publisher","first-page":"e00957","DOI":"10.1002\/prp2.957","volume":"10","author":"D Kleinermans","year":"2022","unstructured":"Kleinermans D, Joyson A, Wray H (2022) An open-label randomized study of the relative absorption of gastro-resistant risedronate taken fasted or with food versus immediate-release risedronate. Pharmacol Res Perspect 10:e00957. https:\/\/doi.org\/10.1002\/prp2.957","journal-title":"Pharmacol Res Perspect"},{"key":"2272_CR66","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Balske A, Burgio DE et al (2013) Treatment of postmenopausal osteoporosis with delayed-release risedronate 35\u00a0mg weekly for 2\u00a0years. Osteoporos Int 24:301\u2013310. https:\/\/doi.org\/10.1007\/s00198-012-2175-7","journal-title":"Osteoporos Int"},{"key":"2272_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","volume":"23","author":"MR McClung","year":"2012","unstructured":"McClung MR, Miller PD, Brown JP et al (2012) Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 23:267\u2013276. https:\/\/doi.org\/10.1007\/s00198-011-1791-y","journal-title":"Osteoporos Int"},{"key":"2272_CR68","first-page":"186","volume":"37","author":"E Casado","year":"2022","unstructured":"Casado E, Palacios S, Thomasius F et al (2022) Not all oral bisphosphonates are equal: risedronate gastro-resistant is more effective than oral alendronate at reducing fractures and lowering healthcare cost. J Bone Miner Res 37:186\u2013187","journal-title":"J Bone Miner Res"},{"key":"2272_CR69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30:45\u201357. https:\/\/doi.org\/10.1007\/s00198-018-4744-x","journal-title":"Osteoporos Int"},{"key":"2272_CR70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00198-020-05802-5","volume":"32","author":"M Hiligsmann","year":"2021","unstructured":"Hiligsmann M, Maggi S, Veronese N et al (2021) Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporos Int 32:595\u2013606. https:\/\/doi.org\/10.1007\/s00198-020-05802-5","journal-title":"Osteoporos Int"}],"updated-by":[{"DOI":"10.1007\/s40520-022-02319-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000}}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-022-02272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-022-02272-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-022-02272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T07:27:57Z","timestamp":1672730877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-022-02272-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s40520-022-02272-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40520-022-02319-1","asserted-by":"object"}]},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the published article, the author would like to update the following lines History of Gastrointestinal symptoms were observed in 31% (n=319) participants and, of these, 85% (n =271) were upper gastrointestinal","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40520-022-02319-1","URL":"https:\/\/doi.org\/10.1007\/s40520-022-02319-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NRF, NA-D, OBo, JB, ECav, MdW, PH, NCH, JMK, AK, RM, SMi, SP, JAK, RR, CC have no conflicts of interest to declare. OBr reports consulting or lecture fees for Amgen, Aptissen, Biophytis, IBSA, MEDA, Mylan, Novartis, Sanofi, TRB Chemedica, UCB, Viatris outside this manuscript. ECas reports Advisory Board participation and lecture fees for Theramex. BC reports Advisory Board participation and lecture fees for Theramex and Advisory Board participation for Expanscience. AG reports consulting and lecture fees from Abiogen Pharma, Theramex, and Bruno. MH has received research grants through institution from Radius Health, Amgen and ViiV Healthcare, lecture fees from Teva and Mylan Pharmaceuticals and consulting fees from UCB. SMa has received grants from Sanofi, MSD, GSK, Pfizer and Viatris outside of the submitted work. RPR has received fees for lectures or scientific advisory boards from Abiogen, Danone, Echolight, European Milk Forum, ObsEva, Pfizer Consumer Health and Theramex. FT reports Advisory Board participation and lecture fees for Theramex. NV reports personal fees from IBSA, Mylan, Viatris, Fidia, MSD outside of the submitted work. JYR reports consulting fees or paid advisory boards for IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer, Mithra Pharmaceutical; lecture fees when speaking at the invitation of sponsor for IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council (DRC), Nutricia, Danone, Agnovos and grant support (through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health, TRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this retrospective review, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The choice of topics, participants, content and agenda of the Working Groups as well as the writing, editing, submission and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Content to participants"}},{"value":"This article is a retrospective review. To the authors\u2019 knowledge, the reviewed studies were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}}]}}